Somagenetix AG secures CHF 10 million in Series A financing to advance lentiviral gene therapy for Chronic Granulomatous Disease (CGD)
08. Oktober 2024 04:00 ET
|
Somagenetix AG
ZURICH, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Somagenetix AG, a pioneering biotech company dedicated to revolutionizing gene therapy for phagocyte disorders, announced today the initial closing of its...
Horizon Pharma plc Launches CGD Connections™ to Deliver Support and Resources Created by and for the Chronic Granulomatous Disease (CGD) Community
25. Juli 2017 08:00 ET
|
Horizon Pharma plc
DUBLIN, Ireland, July 25, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and...